AstraZeneca: FDA Accepts Imfinzi Supplemental Biologics License Application; Grants Priority Review
October 17 2017 - 3:01AM
Dow Jones News
By Josee Rose
AstraZeneca PLC (AZN) on Tuesday said the U.S. Food and Drug
Administration has accepted a supplemental biologics license
application for Imfinzi, granting the drug Priority Review
status.
Imfinzi is being developed to treat patients with stage 3
unresectable non-small cell lung cancer whose disease hasn't
progressed after some chemoradiation therapy.
Imfinzi has had positive data from a phase 3 trial, which
continues to evaluate overall survival, one of its primary
endpoints.
Write to Josee Rose at josee.rose@wsj.com.
(END) Dow Jones Newswires
October 17, 2017 02:46 ET (06:46 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024